A Phase I Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs JNJ 89402638 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 04 Nov 2024 New trial record